These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31335544)

  • 21. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes.
    Wehner M; Rueffert H; Koenig F; Meinecke CD; Olthoff D
    Cell Calcium; 2003 Aug; 34(2):163-8. PubMed ID: 12810058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonanesthetic malignant hyperthermia.
    Lehmann-Horn F; Klingler W; Jurkat-Rott K
    Anesthesiology; 2011 Nov; 115(5):915-7. PubMed ID: 21878807
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families.
    Gillies RL; Bjorksten AR; Du Sart D; Hockey BM
    Anaesth Intensive Care; 2015 Mar; 43(2):157-66. PubMed ID: 25735680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
    Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Modern diagnostic approaches to malignant hyperthermia susceptibility].
    Kazantseva AA; Lebedinskiĭ KM
    Anesteziol Reanimatol; 2014; 59(4):64-8. PubMed ID: 25549489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Confirmation of nonanesthetic-induced malignant hyperthermia.
    Larach MG; Allen GC; Rosenberg H
    Anesthesiology; 2012 Jun; 116(6):1398-9; author reply 1399-400. PubMed ID: 22617205
    [No Abstract]   [Full Text] [Related]  

  • 28. Continued progress in understanding the molecular genetics of malignant hyperthermia.
    Rosenberg H
    Can J Anaesth; 2011 Jun; 58(6):489-93. PubMed ID: 21455644
    [No Abstract]   [Full Text] [Related]  

  • 29. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells.
    Sato K; Roesl C; Pollock N; Stowell KM
    Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Malignant hyperthermia as a complication of anesthesia: predisposition is hereditary].
    Snoeck MM; Gielen MJ; Sengers RC; Padberg GW; Iles DE; Booij LH
    Ned Tijdschr Geneeskd; 1997 Mar; 141(13):616-9. PubMed ID: 9190536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. XXIVth Annual Meeting of the European Malignant Hyperthermia Group.
    Brandom BW; Muldoon SM
    Anesthesiology; 2005 Dec; 103(6):1324. PubMed ID: 16306761
    [No Abstract]   [Full Text] [Related]  

  • 33. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser.
    Girard T; Suhner M; Levano S; Singer M; Zollinger A; Hofer CK
    Anesth Analg; 2008 Dec; 107(6):1953-5. PubMed ID: 19020143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility.
    Robinson RL; Carpenter D; Halsall PJ; Iles DE; Booms P; Steele D; Hopkins PM; Shaw MA
    Br J Anaesth; 2009 Aug; 103(2):220-5. PubMed ID: 19454545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia.
    Manning BM; Quane KA; Lynch PJ; Urwyler A; Tegazzin V; Krivosic-Horber R; Censier K; Comi G; Adnet P; Wolz W; Lunardi J; Muller CR; McCarthy TV
    Hum Mutat; 1998; 11(1):45-50. PubMed ID: 9450902
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel mutation in the RYR1 gene (R2454C) in a patient with malignant hyperthermia.
    Gencik M; Gencik A; Mortier W; Epplen JT
    Hum Mutat; 2000 Jan; 15(1):122. PubMed ID: 10612851
    [No Abstract]   [Full Text] [Related]  

  • 38. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.
    Urwyler A; Deufel T; McCarthy T; West S;
    Br J Anaesth; 2001 Feb; 86(2):283-7. PubMed ID: 11573677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of human cultured myotubes responses mediated by ryanodine receptor 1.
    Kobayashi M; Mukaida K; Migita T; Hamada H; Kawamoto M; Yuge O
    Anaesth Intensive Care; 2011 Mar; 39(2):252-61. PubMed ID: 21485675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recrudescence of malignant hyperthermia.
    Hopkins PM
    Anesthesiology; 2007 May; 106(5):893-4. PubMed ID: 17457116
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.